EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Toxicity of CAR T-Cell Therapy for Multiple Myeloma

Aimaz Afrough, Pearl Rajan Abraham, Laura Turer, Gurbakhash Kaur, Aishwarya Sannareddy, Doris K Hansen, Larry D Anderson

Acta Haematologica · 2024

DOI: 10.1159/000539134 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Haematologica, 2024. Verfasst von Aimaz Afrough und 6 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT South…. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are novel chimeric antigen receptor (CAR)-T cell therapies targeting B-cell maturation antigen (BCMA), and both have recently gained approval by the US Food Drug Administration (FDA) for the treatment of relapsed and refractory multiple myeloma (RRMM). Summary: These therapies offer unprecedented responses in RRMM but present new challenges including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), non-ICANS neurotoxicity, cytopenias, infections, and hypogammaglobulinemia. Key Messages: In the evolving CAR-T landscape, a primary objective is to develop innovative strategies for managing associated toxicities. Through meticulous exploration of underlying mechanisms and tailored interventions, we aim to enhance safety and enable broader outpatient utilization. Refinement of protocols, biomarker identification, and robust monitoring are imperative for sustained efficacy. This comprehensive approach guarantees the continuous advancement and optimization of CAR-T therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansCytokine Release SyndromeB-Cell Maturation AntigenNeurotoxicity SyndromesAntigens, CD19

Stichwörter der Autor:innen

CAR-T therapyMultiple myelomaToxicity

Substanzen

Receptors, Chimeric AntigenB-Cell Maturation AntigenAntigens, CD19idecabtagene vicleucel

Autor:innen und Institutionen

  • Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

Zitieren

APA

Afrough, A., Abraham, P. R., Turer, L., Kaur, G., Sannareddy, A., Hansen, D. K., & Anderson, L. D. (2024). Toxicity of CAR T-Cell Therapy for Multiple Myeloma. Acta Haematologica. https://doi.org/10.1159/000539134

Vancouver

Afrough A, Abraham PR, Turer L, Kaur G, Sannareddy A, Hansen DK, et al. Toxicity of CAR T-Cell Therapy for Multiple Myeloma. Acta Haematologica. 2024. doi:10.1159/000539134

BibTeX
@article{Afrough2024,
  author = {Afrough, Aimaz and Abraham, Pearl Rajan and Turer, Laura and Kaur, Gurbakhash and Sannareddy, Aishwarya and Hansen, Doris K and Anderson, Larry D},
  title = {Toxicity of CAR T-Cell Therapy for Multiple Myeloma},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000539134}
}
Kostenlos starten →